Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zydus Pharmaceuticals (USA) Inc.

Division of Zydus Cadila
www.zydususa.com

Latest From Zydus Pharmaceuticals (USA) Inc.

AndroGel Competitors Enter US After Perrigo’s Exclusivity Expires

Following the expiry of Perrigo’s 180-day exclusivity for its generic version of AndroGel, firms including Lupin and Teva have launched their own generic testosterone 1.62% gels in the US.

Launches Generic Drugs

Generic Sensipar: Cipla Challenges Legality of Amgen/Teva Patent Settlement

Cipla, which previously settled with Amgen, alleges Sensipar's formulation patent is currently unenforceable due to ‘patent misuse,’ and brand sponsor’s deal with Teva following a brief generic launch violates federal antitrust law and California state law.

Generic Drugs Intellectual Property

Record Dr Reddy's US Launches In Q3 Set Tone For Earnings Pick Up?

Dr Reddy’s has had a record number of US launches in Q3 with potentially more in store and now a new US CEO to steer things through, improving outlook for a significant revival in earnings. But risks of delays and competition in certain key anticipated launches in 2019 could dull prospects.
Commercial Strategy

Launch Abbreviated: Teva Halts US Generic Sensipar Sales After Patent Deal With Amgen

In the course of a week, Teva received final ANDA approval for cinacalcet, launched its generic and reached a deal with Amgen to come off the market until mid-2021. The fast but short launch allowed Teva to take some sales away from Amgen without triggering entry of other ANDA sponsors who previously settled, Bernstein Senior Analyst Ronny Gal says.

Generic Drugs Intellectual Property
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Zydus Cadila
  • Senior Management
  • Joe Renner, CEO
  • Contact Info
  • Zydus Pharmaceuticals (USA) Inc.
    Phone: (609) 730-1900
    73 Route 31 N.
    Pennington, NJ 08534
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register